The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention
and rehabilitation requires frequent update of existing guidelines. This review is aimed at …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant
tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …

Mycobacterium tuberculosis strains resistant to almost all available anti-tuberculosis drugs
are an increasing threat to public health worldwide. Among existing drugs with potential …

As recommended by the World Health Organization (WHO), optimal management of MDR-TB
cases can be ensured by a multi-speciality consultation body known as ‘TB Consilium’. …

No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate
to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The …

No large study to date has ever evaluated the effectiveness, safety and tolerability of
imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-…

The World Health Organization (WHO) recommends countries introduce new anti-TB drugs
in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively …

Multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are growing
clinical and public health concerns, with an estimated worldwide incidence and mortality …

The World Health Organization launched a global initiative, known as aDSM (active TB drug
safety monitoring and management) to better describe the safety profile of new treatment …